Mersana Therapeutics, Inc., a biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Fleximer&reg; technology, today announced the completion of a $33 million Series C financing led by new investor Wellington Management Company.<br /> &nbsp;